FilingSEC EDGAR6-K
XORTX Therapeutics Prepares FDA IND Submission for Gout Treatment XRx-026
· SEC accepted
Stagepre-clinical
Filing content
The company plans to submit an Investigational New Drug application to the FDA for its gout program XRx-026 in the fourth quarter of 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…